Celularity, Inc.

CELU Healthcare Biotechnology

Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024. In the quarter to March 2026, revenue fell 66.3%, EPS grew 103.6%, free cash flow grew 148.4% and total debt fell 4.73%, each against the same quarter a year earlier.

1.25 0.08 −6.02%
Market cap
$43.2M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
1/9
Altman Z
−15.22
Beneish M
−5.93
Dividend safety
n/a
Mar '26 Dec '25 Sep '25 Jun '25 Older periods
Piotroski F-Score
1 1 1 3

+8 more TTM periods

ROE
349.83% 628.23% 5,736.39% (6,372.77%)
ROA
(62.45%) (76.50%) (66.41%) (57.65%)
ROIC
(695.71%) (1,070.92%) (153.64%) (172.59%)
Return on Tangible Assets
734.06% 726.09% (3,220.71%) (1,099.18%)
Average Days of Receivables
91.99 63.97 60.31 91.29
Free Cash Flow per Share
(0.30) (0.52) (0.25) (0.11)
Free Cash Flow
(8.81) (13.25) (6.56) (2.54)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 1 Oct 2026